UroGen Pharma Ltd. (NASDAQ:URGN – Get Rating) – Equities researchers at Oppenheimer issued their FY2027 earnings estimates for shares of UroGen Pharma in a report issued on Tuesday, March 28th. Oppenheimer analyst L. Gershell forecasts that the company will post earnings per share of $7.24 for the year. The consensus estimate for UroGen Pharma’s current […]
UroGen Pharma (NASDAQ:URGN – Get Rating) and PDS Biotechnology (NASDAQ:PDSB – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk. Analyst Recommendations This is a breakdown of current ratings […]
Wall Street analysts predict that UroGen Pharma Ltd. (NASDAQ:URGN – Get Rating) will post earnings of ($1.32) per share for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for UroGen Pharma’s earnings. The lowest EPS estimate is ($1.69) and the highest is ($1.12). UroGen Pharma posted earnings of ($1.17) per share during […]
Equities analysts expect that UroGen Pharma Ltd. (NASDAQ:URGN – Get Rating) will report ($1.36) earnings per share for the current quarter, according to Zacks. Three analysts have made estimates for UroGen Pharma’s earnings, with the highest EPS estimate coming in at ($1.18) and the lowest estimate coming in at ($1.58). UroGen Pharma posted earnings of […]
UroGen Pharma (NASDAQ:URGN – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Friday, Zacks.com reports. According to Zacks, “UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The company’s product […]